Grey Horizon

  To all Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume the week of June 22, 2026. 

 Findings from EXTEND, "a multicentre, open-label, parallel group, superiority-design phase II randomized study conducted among patient...

 Findings from the NordiCC (Nordic Colorectal Cancer) group, a 13-year follow-up study that "enrolled men and women aged 55-64 years, w...

 New research, set to be discussed at the European Society for Medical Oncology [ESMO] Breast Cancer Congress (May 6-8, 2026 in Berlin) purp...

Results of an open-label phase II randomized study, conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University ...

Findings from the COMPASS trial, aimed at establishing "the feasibility of a comprehensive real-time genomic analysis of pancreatic duc...

 Findings from a recent study presented at the ESMO Sarcoma and Rare Cancer Congress indicate a substantial gap between precision oncology a...

The European Society for Medical Oncology (ESMO) recently unveiled a draft report on "preventing work-related psychosocial risks that c...

  Over the past few years, artificial intelligence (AI) has placed an increasing role in cancer research. AI tools "can be used to help...

 Results from a recent ESMO (European Society for Medical Oncology) and EURACAN (European Reference Network to Cancers) had led to a "c...

 Findings from SONIA, a phase III Dutch study comparing "the sequence of an aromatase inhibitor plus CDK4/6 inhibitor as first-line tre...

 A recently completed study at the University Hospital of Toulouse, France emphasized the benefits of a "domain-specific natural langua...

A recently published U.S. population-based cohort study found "significant reductions in 1-year cause-specific survival rates among pat...

Trustworthiness of artificial intelligence (AI) applications and validating data analysis in cancer care was recently discussed at the ESMO ...

 The Experimental Oncology Group at the National Research Centre (CNIO) in Madrid has recently unveiled findings from genetically engineered...

 The European Society of Medical Oncology (ESMO) has released an update to their colon cancer guidelines, whereby "physical activity, w...

 The European Parliament recently adopted first-reading of the Critical Medicines Act, expanding "collaborative procurement and solidar...

Researchers from the Gray Faculty of Medical and Health Sciences in Tel Aviv, in partnership with researchers in 14 laboratories in Israel, ...

 To all Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume the week of January 5, 2026.  Season...

 Study results currently being presented at the ESMO Immuno-Oncology Congress (held in London, England, December 10-12, 2025) showcase the r...

 Recently, at the ESMO Asia Congress 2025, emphasis was placed on the diagnosis of cancer in adolescents and young adults (AYA), which ...

 The European Society for Medical Oncology (ESMO) has released the Basic Requirements for AI-Based Biomarkers in Oncology (EBAI) framework, ...

The European Society for Medical Oncology (ESMO) recently launched the inaugural Congress on Artificial Intelligence and Digital Oncology, t...

 Results of ATHENA-MONO/GOG-3020/ENGOT-ov45, a phase III trial investigating rucaparib as a monotherapy in first-line maintenance treatment ...

 Results from TUXEDO-3, a prospective multicentre open-label single-arm multicohort phase II study were recently published on The Lancet Onc...

A recent editorial published in the ESMO Daily Reporter raises questions about the impact of precision medicine in personalized cancer care,...

A recent international study focused on immune checkpoint inhibitor treatment has shown that higher thymic health was associated with a 35% ...

 Findings from Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging (RIC) a cohort study of 3 700 000 children from Canad...

 A recent study published in Science  provides proof-of-concept that "generative artificial intelligence can offer a valid alternative ...

A recently published phase III trial in Lancet Oncology, lower doses of adjuvant radiotherapy plus docetaxel "were associated with redu...